# A Study of Rofecoxib in the Treatment of Post-Operative Pain After Total Knee Joint Replacement (0966-259)

> **NCT00140920** · PHASE4 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 11 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** MK0966; rofecoxib
- **DRUG:** Comparator: diclofenac 2x 75 mg

## Key facts

- **NCT ID:** NCT00140920
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-05-25
- **Primary completion:** 2004-09-27
- **Final completion:** 2004-09-27
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Recruitment/study discontinued after withdrawal of marketing authorisation. No data entered.
- **Last updated:** 2017-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00140920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00140920, "A Study of Rofecoxib in the Treatment of Post-Operative Pain After Total Knee Joint Replacement (0966-259)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00140920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*